Valganciclovir-d8 (hydrochloride)

• UNSPSC Description:

  Valganciclovir-d8 (hydrochloride) is the deuterium labeled Valganciclovir hydrochloride[1]. Valganciclovir hydrochloride, the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir[2][3][4].

• Target Antigen:

  CMV

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])[C@@](N)([2H])C(OCC(CO)OCN1C2=C(C(N=C(N2)N)=O)N=C1)=O

• Molecular Weight:

  362.41

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.|[3]Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun14(3):259-67.|[4]O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15111(4):1816-9.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1132088-63-1